Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: J Pediatr Gastroenterol Nutr. 2019 Jul;69(1):68–74. doi: 10.1097/MPG.0000000000002304

Figure 1. Infliximab trough concentrations for primary and second outcomes.

Figure 1.

(A) Clinical response at infusion 4 was determined by improvement in the baseline wPCDAI (delta >17.5) and remaining on infliximab without surgery. (B) Biological response at infusion 4 was defined by >50% improvement from the baseline fecal calprotectin. Drug concentrations at each infusion were compared with the Mann-Whitney test.